Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Nail psoriasis is a common clinically significant symptom of psoriasis. However, few studies have focused on the characteristics and course of toenail psoriasis. Objective: To investigate the treatment response of toenail psoriasis during a 52-week period of ustekinumab use. Methods: Patients were evaluated using the Nail Psoriasis Severity Index (NAPSI) at every injection visit. NAPSI score changes throughout the treatment were analyzed. The treatment response in each toenail and each NAPSI characteristic was also analyzed. Results: A total of 22 patients with chronic plaque psoriasis with concomitant toenail psoriasis were examined. Several characteristics such as ridging or onychomycosis that mimic psoriasis or hinder the evaluation were identified. NAPSI significantly improved during the treatment (p＜0.05). The big and second toes were significantly improved after 52 weeks of ustekinumab treatment (p＜0.05). Pitting and oil-drop discoloration were the only two characteristics that showed significant changes post-treatment (p＜0.05). Conclusion: Ustekinumab proved to be efficacious in treating toenail psoriasis. Because of the factors that hinder the NAPSI scoring, only NAPSI scores of the first and second toes can be used.
Abstract
Background: Nail psoriasis is a common clinically significant symptom of psoriasis. However, few studies have focused on the characteristics and course of toenail psoriasis. Objective: To investigate the treatment response of toenail psoriasis during a 52-week period of ustekinumab use. Methods: Patients were evaluated using the Nail Psoriasis Severity Index (NAPSI) at every injection visit. NAPSI score changes throughout the treatment were analyzed. The treatment response in each toenail and each NAPSI characteristic was also analyzed. Results: A total of 22 patients with chronic plaque psoriasis with concomitant toenail psoriasis were examined. Several characteristics such as ridging or onychomycosis that mimic psoriasis or hinder the evaluation were identified. NAPSI significantly improved during the treatment (p＜0.05). The big and second toes were significantly improved after 52 weeks of ustekinumab treatment (p＜0.05). Pitting and oil-drop discoloration were the only two characteristics that showed significant changes post-treatment (p＜0.05). Conclusion: Ustekinumab proved to be efficacious in treating toenail psoriasis. Because of the factors that hinder the NAPSI scoring, only NAPSI scores of the first and second toes can be used.
참고문헌 (30)
- Farber EM, "Nail psoriasis", Cutis, 50, pp.174~178 (1992)
- Augustin M, "Nail psoriasis in Germany : epidemiology and burden of disease", Br J Dermatol, 163, pp.580~585 (2010)
- Klaassen KM, "Nail Psoriasis, the unknown burden of disease", J Eur Acad Dermatol Venereol, 28, pp.1690~1695 (2014)
- Radtke MA, "Nail psoriasis as a severity indicator : results from the PsoReal study", Patient Relat Outcome Meas, 2, pp.1~6 (2011)
- Lin TY, "Quality of life in patients with psoriasis in northern Taiwan", Chang Gung Med J, 34, pp.186~196 (2011)
- Herédi E, "Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary", Eur J Health Econ, 15(Suppl 1), pp.S111~S119 (2014)
- Rich P, "Nail Psoriasis Severity Index : a useful tool for evaluation of nail psoriasis", J Am Acad Dermatol, 49, pp.206~212 (2003)
- Ortonne JP, "Development and validation of nail psoriasis quality of life scale(NPQ10)", J Eur Acad Dermatol Venereol, 24, pp.22~27 (2010)
- 최지웅, "Could Psoriatic Arthritis Be Easily Diagnosed from Current Suspicious Physical Findings in the Dermatology Clinic?", Annals of Dermatology, 29(1), pp.48~54 (2017), 대한피부과학회
- Taylor W, "Classification criteria for psoriatic arthritis : development of new criteria from a large international study", Arthritis Rheum, 54, pp.2665~2673 (2006)
- Langenbruch A, "Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis", Br J Dermatol, 171, pp.1123~1128 (2014)
- Youn SW, "Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab : the MARCOPOLO study", J Eur Acad Dermatol Venereol, 31, pp.e298~e299 (2017)
- Ortonne JP, "A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis", Br J Dermatol, 168, pp.1080~1087 (2013)
- Patsatsi A, "Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study", J Dermatolog Treat, 24, pp.96~100 (2013)
- Rich P, "Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1", Br J Dermatol, 170, pp.398~407 (2014)
- Armstrong AW, "Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis", J Clin Aesthet Dermatol, 9(6 Suppl 1), pp.S12~S16 (2016)
- van de Kerkhof P, "Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis:results from the randomized, controlled and open-label phases of UNCOVER-3", J Eur Acad Dermatol Venereol, 31, pp.477~482 (2017)
- Reich K, "Effect of secukinumab on the clinical activity and disease burden of nail psoriasis : 32-week results from the randomized placebo-controlled TRANSFIGURE trial", Br J Dermatol, 181, pp.954~966 (2019)
- Brazzelli V, "Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients:Italian experience", J Eur Acad Dermatol Venereol, 26, pp.1354~1359 (2012)
- Rigopoulos D, "Efficacy of ustekinumab in nail psoriasis and improvement in nailassociated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study", Dermatology, 223, pp.325~329 (2011)
- Vitiello M, "Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients", Int J Dermatol, 52, pp.358~362 (2013)
- Kim BR, "Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab", J Dermatolog Treat, 30, pp.123~128 (2019)
- Liang CY, "Successful treatment of pediatric nail psoriasis with periodic pustular eruption using topical indigo naturalis oil extract", Pediatr Dermatol, 30, pp.117~119 (2013)
- 변상영, "Severe Nail Fold Psoriasis Extending from Nail Psoriasis Resolved with Ustekinumab: Suggestion of a Cytokine Overflow Theory in the Nail Unit", Annals of Dermatology, 28(1), pp.94~97 (2016), 대한피부과학회
- Baran R, "The nail in the elderly", Clin Dermatol, 29, pp.54~60 (2011)
- Singh G, "Nail changes and disorders among the elderly", Indian J Dermatol Venereol Leprol, 71, pp.386~392 (2005)
- Choi JW, "Identification of nail features associated with psoriasis severity", J Dermatol, 44, pp.147~153 (2017)
- Klaassen KM, "The prevalence of onychomycosis in psoriatic patients : a systematic review", J Eur Acad Dermatol Venereol, 28, pp.533~541 (2014)
- Elewski BE, "Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial", J Am Acad Dermatol, 78, pp.90~99 (2018)
- de Berker D, "Management of nail psoriasis", Clin Exp Dermatol, 25, pp.357~362 (2000)